Bayer
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher following U.S. approval ...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into ...
Latest News
6 days ago · zacks.com
Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk ReductionBayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.
7 days ago · businesswire.com
Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S.WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat.
8 days ago · zacks.com
3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
12 days ago · zacks.com
BAYRY vs. JNJ: Which Stock Is the Better Value Option?Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Bayer Aktiengesellschaft (BAYRY) and Johnson & Johnson (JNJ). But which of these two stocks is more attractive to value investors?
12 days ago · zacks.com
Are Medical Stocks Lagging Bayer (BAYRY) This Year?Here is how Bayer Aktiengesellschaft (BAYRY) and Encompass Health (EHC) have performed compared to their sector so far this year.
13 days ago · businesswire.com
Bayer and America's Grow-a-Row Continue Partnership to Fight Food InsecurityPITTSTOWN, N.J.--(BUSINESS WIRE)-- #TeamBAYER--In 2026, Bayer and America's Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious produce for communities across the United States. Key Facts More than 200 Bayer employees volunteered with America's Grow-a-Row on August 27 and October 1. Volunteers harvested 165,500 pounds of produce, equivalent to approximately 662,000 servings. Since 2020, Bayer Fund has provided more than $500,000 in grants to A.
13 days ago · reuters.com
Bayer seeks bigger role in fast-growing Latin American biologicals marketBayer seeks bigger role in fast-growing Latin American biologicals market
13 days ago · zacks.com
BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs WellBayer's Q3 earnings and revenues miss estimates, but strong growth in Nubeqa and Kerendia boosts pharma performance and lifts 2026 EBITDA guidance.
13 days ago · businesswire.com
Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific SessionsWHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific Sessions in Chicago, Illinois from November 6-9, 2026. Key Facts A late-breaking oral presentation will feature data from an exploratory post-hoc analysis of the Phase 3 OCEANIC-STROKE study, which evaluated asundexian versus placebo, both in combination with antiplatelet therapy, in patients after.
13 days ago · seekingalpha.com
Bayer AG: Solid Q3 Earnings, But Still A 'Prove-It' StoryBayer A.G. maintains a 'Hold' rating after a robust Q3, with Pharma outperforming expectations and driving operating leverage. Q3 Pharma EBITDA before special items rose 23.6% to 1.292 billion euro, with margins improving to 27.6% from 24.1%. Core free cash flow guidance (ex-settlements) was upgraded to €3–4 billion, with settlement outflows peaking in 2026 and tapering thereafter.
Earnings
Add to Watchlist
Select watchlists to add or remove BAYRY